Last reviewed · How we verify
NCT03542357
The Effect of Sumatriptan and Placebo on CGRP Induced Headache
NA trial testing Calcitonin Gene Related Peptide in Migraine in 30 participants. Completed in 1 September 2018.
1 September 2018
Quick facts
| Lead sponsor | Danish Headache Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 15 February 2018 |
| Primary completion | 1 September 2018 |
| Estimated completion | 1 September 2018 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Calcitonin Gene Related Peptide
- Sumatriptan 50 mg — full drug profile →
- Placebo Oral Tablet — full drug profile →
Conditions studied
- Migraine — all drugs for Migraine →
Sponsor
Danish Headache Center — full company profile →
Who can join
Adults 18 to 60, any sex, with Migraine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To develop a pragmatic migraine model the investigators will induce headache in healthy volunteers and in patients with migraine without aura with aCalcitonine Gene Related Peptide (CGRP). If the headache responds to sumatriptan, the model can be used to test new drug candidates.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Neuro-Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets.
Guo X, Liu H, Song YJ, Wang JH, et al · · 2026 · cited 2× · PMID 41583906 · DOI 10.1002/mco2.70497
Verify or expand the search:
- PubMed search for NCT03542357
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Migraine
Currently open trials in the same condition.
- NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
- NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
- NCT07343427 — Impact of GON PRF on Central Sensitization in Migraine Patients · NA · active not recruiting
- NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
- NCT07385755 — Desvenlafaxine for Preventive Treatment of Frequent Migraines · NA · active not recruiting
Other Danish Headache Center trials
Trials by the same sponsor.
- NCT07451769 — Selective Activation of the Adrenomedullin Receptors in Migraine · NA · not yet recruiting
- NCT07342296 — Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38 · NA · not yet recruiting
- NCT07059546 — Hypersensitivity to Adrenomedullin in Post-Traumatic Headache · NA · recruiting
- NCT07021859 — Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide · NA · recruiting
- NCT06959004 — Substance P-Induced Migraine Attacks Without Aura · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03542357 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Danish Headache Center
- Last refreshed: 12 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03542357.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing